Introduction
Inflammation of lower airways characterizes the lung injury and fibrosis In interstitial lung disease [ILD] . Clearance of inhaled technetium-labeled diethylenetriamine pentaacetate [ 99m Tc-DT-PA] from the lung is an index of lung epithelial permeability [1] . Increased DTPA clearance may be a sensitive marker of inflammation [2] and normal clearance certifies absence of inflammation [3] . It is abnormal in several ILD, it has been used as a marker of alveolar inflammation in sarcoidosis [3, 4] and could potentially be used as a predictor of disease progression in Idiopathic Pulmonary Fibrosis (IPF) [5] . On the contrary, recent data suggest that 99m Tc-DTPA is weakly associated with high-resolution computed tomography (HRCT) in IPF, while has been found abnormal in the majority of the evaluated patients [6] . The technique is non invasive, relatively inexpensive with a low radiation, and easy to perform using standard equipment in clinical nuclear medicine departments [7, 8] .
HRCT has diagnostic and prognostic value, and should be a part of the initial evaluation of ILD [9] . For most sarcoidosis patients, HRCT scans are indicated [10] .
The objective of this study was to explore the degree of association of HRCT score of pulmonary and lymph node involvement and the rate of clearance of 99m Tc-DTPA in sarcoidosis patients. Furthermore, we investigated the correlation between the rate of DTPA clearance and certain indices of pulmonary function tests [PFTs] . the measurement of DTPA clearance. According to chest radiography classification of sarcoidosis, 5 had type I disease, 7 type II, and 3 type III disease [10] .
Methods

Patients
Methods
Spirometry was performed with a computerized system [MasterLab, Jaeger2.12, Germany]. The measurement was performed using standard protocols according to American Thoracic Society (ATS) guidelines [11] . Subjects did not use short acting bronchodilators within 12 hours prior to the measurements. The best of three consecutive measurements was chosen.
HRCT in sarcoidosis patients
CT scoring included the sum of the severity and extent of lymph node enlargement at three different sites (paratracheal, mediastinal/carina, hilar) and the parenchymal involvement [peribronchial thickening, nodules, collapse/consolidation/pseudoalveolar opacities, ground glass, and reticulation/honeycombing].
For lymph node involvement, mediastinal windows and levels were used and a semi-quantitative grading was done ranging from 0-1 for each of the above lymph node sites as follows: No lymph node enlargement was graded as 0; lymph nodes with a diameter <10 mm as 1, and nodes >10 mm as 2. Therefore for a patient with all the above lymph sites involved the maximum score would be 6.
For parenchymal evaluation HRCT images were used and were subsequently evaluated at five different levels recording the relative proportion of all the above findings to within 5%. Scores from the five HRCT slices were summed and divided by the total number of slices to calculate the average extent score for each of the variables. The levels of evaluation included the vascular pedicle, the tracheal carina, the pulmonary hilum, the pulmonary venous confluence, and 1-2 cm above the right diaphragm. The scans were performed with 1 mm thickness and a 1 to 2 s scanning time during breath holding at end inspiration. High spatial frequency algorithm was used and images were read at window levels appropriate for pulmonary parenchyma (level -600 to -700 Hounsfield units: width 1600 Hounsfield units). For evaluation of extent of parenchymal involvement was assessed by HRCT slices using a visual method, similar to that used previously by other investigators [12, 13] . For each of the parenchymal features evaluated: 1. peribronchial thickening, 2. nodules, 3. collapse/consolidation/pseudoalveolar opacities, 4. ground glass, and 5. reticulation/honeycombing] quantification was done as follows: no abnormality graded as 0; extent <25% as 1; extent 25-50% as 2; extent >50% as 3. Therefore, for each patient the range of lung parenchyma score would be 0-15. The maximum sum of involvement for each patient is 21 (15+6). This scoring system is similar to the Oberstein et al. scoring with a slight modification [in our study we did not evaluate pleural changes as in previous studies were not correlated with any disease activity index] [12] . Regions of interest [ROI] were identified on either lung and a background ROI was set. Background subtraction was employed and an exponential fit of the clearance of each lung was derived starting from the frame with peak activity. The halftime of clearance was estimated in minutes for each lung and the average value was obtained. A clearance half-time of <40 min was regarded as abnormal and a clearance half-time of less than 20 min [50% of normal] was categorized as very rapid [5, 14, 15] .
Results
The demographic and clinical characteristics of the sarcoidosis patients are shown in table 1. The mean (mean±SD) DTPA clearance half-time was found 38.3±4.5 min, (range: 31-45). The scans were evaluated as abnormal in 10 of 15 of our patients (66.7%). For lymph node involvement, the scoring system results were 2.07±1.22 (range 0 to 4) and with a 34% in % evaluation. For parenchymal involvement the scoring system results were 2.53±3.48 (range 0 to 10) and with a 12% in a % evaluation. DTPA clearance rate was significantly correlated with HRCT scoring of parenchymal involvement (r= -0.651, p=0.009) (figure 1). The HRCT parenchymal abnormalities were found significantly correlated with PFTs [FVC (r= -0.65, p=0.008) and TLCO (r= -0.76, p=0.02)]. No correlation was found between parenchymal abnormalities and FEV 1 (r= -0.15, p=0.9) such as with TLC (r= -0.29, p=0.2).
No correlation was found between DTPA clearance and PFTs [FEV 1 (r= -0.016, p=0.9), FVC (r= 0.016, p=0.9), TLC (r= 0.14,p=0.6) and TLCO (r=0.2,p=0.5], as well as between DTPA clearance or HRCT score and serum angiotensin converting enzyme (SACE).
Discussion
The present study systematically evaluates newly diagnosed sarcoidosis patients, comparing quantitatively the abnormalities in the HRCT and The most important finding of our study is a moderate correlation between HRCT parenchymal abnormalities and 99m Tc-DTPA clearance time. We also found that HRCT parenchymal abnormalities are significantly correlated with TLCO [(r= -0.767) and with FVC (r= -0.65)]. To the best of our knowledge this is the first study to show the degree of correlation of 99m Tc-DTPA clearance and HRCT in sarcoidosis patients.
In this study, all ten sarcoidosis patients with abnormal DTPA scan presented with pulmonary parenchymal involvement on HRCT [type II or III disease] in agreement with previous studies [16, 17] . Furthermore, no correlation existed between 99m Tc-DTPA clearance time and PFTs or inflammatory markers like ACE in the serum. In accordance with other studies it seems that DTPA clearance reflects lung function abnormalities better than other tests [16] [17] [18] .
In addition, we found a correlation between DTPA clearance and HRCT score, although the minimal lung parenchymal lesions in HRCT (12%). The percentage of HRCT parenchymal abnormalities found in the present study was lower compared to the group of Leung and coworkers reported one to four HRCT features in the total evaluation [19] . Moreover, comparison of HRCT with indices of disease activity (67 Gallium scan, bronchoalveolar lavage [BAL] and SACE) showed that the extent of nodules, and consolidation was well correlated with disease activity. However, activity indices were not correlated with ground glass and linear opacities [19] .
Interstitial fibrosis causing functional impairment may develop in up to 20-25% of patients with sarcoidosis and results in death in 5-10% [20] . HRCT has been accepted as a non invasive tool for early recognition of interstitial lung involvement in sarcoidosis [21] . Additionally, the extent of the interstitial changes in HRCT was well correlated with respiratory functional impairment [19] , while other several studies have reported that HRCT features of air trapping correlated well with obstruction indices in PFTs [22] [23] [24] [25] . The nature of the interstitial and airway involvement in sarcoidosis could explain the discrepancies reported in the fore-mentioned studies [21] [22] [23] [24] [25] .
HRCT parenchymal abnormalities in this study showed a significant correlation with PFTs [TLCO (r= -0.767) and FVC (r= -0.65)]. Many research groups have investigated CT as a non invasive examination in distinguishing patients with active disease and potentially reversible lesionsfrom those with irreversible fibrotic disease [26] [27] [28] . Results of these studies though seem to be inconsistent [19, 16, [28] [29] [30] . However, two studies Oberstein et al. [12] and Leung et al. [19] reported solid evidence of HRCT correlation with disease activity markers such as BAL total cell and lymphocyte counts, IL-2R, CD4/CD8 ratio, IL-2R and HLA-DR. Their results showed that specific HRCT abnormalities including bronchovascular bundle thickening and intraparenchymal nodules correlate well with the above mentioned disease activity markers [12] . Our scoring system practically similar of that used in the study of Oberstein et al. [12] . This scoring system was recently further evaluated by Drent et al. [31] in 80 consecutive sarcoidosis patients and found significant correlation between HRCT scoring and functional parameters. In accordance with these studies the correlation found in this study sustains in all HRCT subscores, except enlargement of lymph nodes.
Mimori Y et al. examined the correlation between the levels of SACE and HRCT in 25 sarcoidosis patients [30] . In this study, the authors did not find a correlation between visual score in HRCT and serum ACE, in according to our data.
Our data suggest that DTPA indicates active disease even in patients with minimal (mild bronchial thickening) or no evidence of HRCT involvement of the lung. However, further studies in a larger number of patients are needed to confirm this correlation of DTPA with the HRCT abnormalities in newly diagnosed sarcoidosis, such as in the follow up of this disease.
